CBD Medication Safety • Evidence-First Guide
CBD Interactions: Medications, Liver Safety, Blood Monitoring, and What to Ask Your Pharmacist
CBD can interact with medications, but not every interaction carries the same level of evidence or the same clinical importance. This guide separates documented human interactions from case reports and enzyme-based predictions, explains where liver and blood monitoring may matter, and shows why dose, formulation, and the exact medication all change the conversation.
Liver safety
Drug levels
Full-Spectrum context
Written by: Bill Polyniak, Founder of Bluegrass Hemp Oil and Kentucky Cannabis Company, for hemp cultivation, extraction, Full-Spectrum formulation, manufacturing, labels, laboratory testing, and product-quality context.
Clinical review status: this revision is prepared for independent pharmacist review of pharmacology, medication interactions, pharmacokinetics, liver safety, therapeutic drug monitoring, and interpretation of clinical literature. Reviewer attribution should be added only after that review is completed.
Quick answer
Can CBD Interact With Medication?
Yes, CBD can interact with some medications. The important question is not simply whether CBD touches a liver enzyme. The clinically useful question is whether a specific CBD exposure meaningfully changes a specific medication's concentration, effect, adverse-effect profile, or monitoring needs in humans.
Not all evidence is equal
A human pharmacokinetic trial is stronger evidence than a laboratory enzyme prediction.
Dose matters
CBD exposure can change the size and clinical relevance of an interaction.
The medication matters
Warfarin, clobazam, valproate, citalopram, and amitriptyline do not share one interaction mechanism.
Monitoring may matter
Liver tests and medication blood levels answer different safety questions.
Evidence hierarchy
Not Every CBD “Interaction” Means the Same Thing
A 2025 scoping review mapped 271 potential CBD interactions across 136 studies. Most were pharmacokinetic, often involving CYP metabolism, but only about 5% of the studies evaluated clinical relevance. That gap is why a responsible interaction guide should label the strength of evidence instead of treating every enzyme pathway as a proven clinical danger.
Clinically demonstrated
Human studies show a measurable change in drug exposure, active metabolite exposure, adverse effects, laboratory values, or required monitoring.
Examples: clobazam's active metabolite; citalopram exposure.
Clinical signal or case reports
Human reports suggest an interaction, but evidence is limited, uncontrolled, or based on small numbers of patients.
Example: warfarin and cannabinoids.
Mechanistically plausible
CBD affects an enzyme or transporter involved with the medication, but a clinically important effect has not necessarily been demonstrated in humans.
Meaning: worth checking, not proof of a dangerous interaction.
Research: Nader et al. (2025), scoping review of CBD drug interactions.
Two different interaction types
CBD Can Change a Drug's Concentration or Add to Its Effects
Pharmacokinetic interaction
CBD changes what the body does to another drug. This can involve absorption, metabolism, transporters, or elimination and can raise or lower drug or metabolite concentrations.
Example: CBD substantially increases exposure to N-desmethylclobazam, clobazam's active metabolite.
Pharmacodynamic interaction
Two substances influence the same body function even if one does not meaningfully change the other's blood concentration.
Example: CBD and another sedating substance may contribute to drowsiness or impairment.
Why this distinction matters: a theoretical CYP interaction, a measured rise in drug concentration, and additive sedation are three different clinical questions. They should not be collapsed into a single list of “drugs that cannot be taken with CBD.”
Exposure changes the question
Dose and Formulation Matter Before You Generalize an Interaction
Much of the best-characterized CBD interaction literature comes from purified prescription cannabidiol or weight-based doses that can produce several hundred milligrams of CBD per day. That evidence proves that cannabidiol can participate in clinically important interactions, but it does not establish that every lower-dose Full-Spectrum preparation produces the same magnitude of effect.
Lower dose does not mean zero interaction risk. A small 2025 healthy-volunteer study found that a single 30 mg purified CBD dose modestly increased amitriptyline exposure, while tramadol exposure was not significantly changed. That is a useful reminder that the exact medication can matter as much as the CBD dose.
Best interpretation: dose, formulation, route, food, liver function, other medications, and the medication's therapeutic window all influence clinical relevance. Evidence from purified CBD should inform Full-Spectrum safety discussions, but it should not be converted into identical risk estimates without direct evidence.
Research: low-dose CBD interaction study with amitriptyline and tramadol.
Liver safety
Liver Metabolism Is Not the Same Thing as Liver Injury
Many medications and cannabinoids are processed through the liver. That fact alone does not mean liver damage will occur. Liver-enzyme elevations are a separate safety outcome measured with blood tests such as ALT and AST.
CBD alone can raise liver enzymes at sufficient exposure
In a 2025 randomized trial, healthy adults received purified CBD at 5 mg/kg/day for 28 days. ALT or AST rose above three times the upper limit of normal in 5.6% of the CBD group and 0% of placebo participants.
Other medications can increase the risk further
Current EPIDIOLEX labeling identifies valproate as an important risk factor for transaminase elevations. In LGS/DS trials, ALT elevations above three times the upper limit of normal occurred in 30% with valproate plus clobazam, 21% with valproate alone, 4% with clobazam alone, and 3% with neither.
This is why the safer conclusion is not “CBD only affects the liver when medication is involved.” CBD itself can be associated with liver-enzyme elevations at sufficient exposure, while certain medication combinations can substantially increase that risk.
For prescription EPIDIOLEX, current labeling calls for ALT, AST, and total bilirubin before treatment, at 1 month, 3 months, and 6 months, and periodically thereafter as clinically indicated. More frequent monitoring may be appropriate with valproate or elevated baseline liver enzymes.
Primary references: Florian et al. (2025) and current EPIDIOLEX prescribing information.
High-value clinical examples
CBD, Clobazam, Valproate, and Other Antiseizure Medications
Antiseizure medications provide some of the clearest human examples of why interaction mechanism matters.
| Medication / issue | What human evidence shows | Why it matters |
|---|---|---|
| Clobazam | CBD had little effect on clobazam itself in a Phase 1 study, but exposure to active metabolite N-desmethylclobazam increased about 3.4-fold. | Can increase clobazam-related adverse effects and sedation. This is a clinically demonstrated pharmacokinetic interaction. |
| Valproate | Dedicated pharmacokinetic studies did not show a clinically important increase in valproate exposure, but concomitant valproate is strongly associated with higher liver-enzyme elevation rates with EPIDIOLEX. | The clinically important issue is liver safety, not simply a large rise in valproate concentration. |
| Other ASMs | Expanded-access studies reported changes in serum concentrations of several antiseizure medications as CBD doses increased. | Medication-specific drug-level monitoring may be useful when clinically indicated. |
Do not treat “seizure medications” as one interaction class. Clobazam, valproate, topiramate, rufinamide, zonisamide, eslicarbazepine, and other antiseizure drugs have different pharmacology and different levels of evidence.
For the deeper prescription-versus-Full-Spectrum comparison, see Epidiolex vs. Full-Spectrum CBD. For the condition-specific consumer guide, see CBD for Seizures.
Research: Morrison et al. Phase 1 clobazam/valproate interaction trial and Gaston et al. antiseizure-drug serum-level study.
Anticoagulant evidence
CBD and Warfarin: A Real Signal, but Not Proof for Every Blood Thinner
Warfarin has published cannabinoid interaction case reports involving elevated INR and, in some cases, warfarin dose reduction. However, a 2023 systematic review found that evidence supporting cannabinoid interactions with other anticoagulants was essentially absent.
Evidence level
Clinical signal / case reports. The review found seven warfarin cases, so certainty remains low.
Exposure matters
Reported cannabinoid doses were often very high or unknown, limiting direct translation to lower-dose consumer CBD use.
Practical takeaway
Someone taking warfarin should discuss CBD with the clinician managing INR. Do not adjust warfarin because of a CBD article.
Research: Smythe et al. (2023), systematic review of cannabinoid-anticoagulant interactions.
Psychiatric medication examples
CBD and Antidepressants: The Exact Drug Matters
“Antidepressants” should not be presented as one uniform CBD-interaction category. Different drugs rely on different metabolic pathways and human studies show different effect sizes.
Citalopram
A 2026 healthy-adult study found that repeated CBD dosing at 2.5 mg/kg twice daily increased citalopram total exposure by about 43% and peak concentration by about 12%.
Evidence level: clinically demonstrated pharmacokinetic interaction in a controlled study.
Amitriptyline
In a small 2025 study, a single 30 mg CBD dose increased amitriptyline AUC by about 13% and peak concentration by about 17%.
Evidence level: human pharmacokinetic signal, but small study and single CBD exposure.
The existence of a human interaction with one antidepressant does not prove the same magnitude of interaction with every SSRI, SNRI, tricyclic antidepressant, or other psychiatric medication.
Research: Salcedo et al. (2026), CBD with citalopram and morphine and 2025 low-dose CBD study with amitriptyline and tramadol.
Concentration is not the whole story
CBD, Sedatives, Alcohol, and Opioids
Some combinations matter because of additive effects such as drowsiness, even if a major change in drug concentration is not demonstrated. Current EPIDIOLEX labeling warns that other central nervous system depressants, including alcohol, can potentiate somnolence and sedation.
At the same time, a 2026 clinical pharmacology study found only limited pharmacokinetic interaction between repeated CBD and morphine. That does not establish that all opioid/CBD combinations are risk-free. It does show why “opioids interact with CBD” is too broad unless the mechanism and evidence are stated.
Use the right question: Is the concern a change in drug concentration, additive sedation, impaired driving, respiratory risk, or something else? Those questions require different evidence.
References: CBD-citalopram/morphine clinical interaction study and EPIDIOLEX prescribing information.
CYP and UGT in plain English
An Enzyme Interaction Does Not Automatically Equal a Dangerous Clinical Interaction
| Concept | What it means | What it does not prove |
|---|---|---|
| CYP inhibition | CBD can reduce activity of certain cytochrome P450 enzymes under some conditions. | It does not prove every medication using that pathway will reach a dangerous concentration. |
| UGT interaction | CBD can affect glucuronidation pathways involved in some drug metabolism. | It does not automatically establish a clinically meaningful interaction at ordinary consumer exposure. |
| Transporter interaction | CBD may alter exposure of some transporter substrates. | A transporter mechanism alone does not tell you the size of the effect in a real patient. |
| Narrow therapeutic window | Small drug-level changes may matter more for certain medications. | The same percentage change does not have equal significance for every drug. |
The current EPIDIOLEX label contains medication-specific recommendations for several enzyme and transporter substrates. That is more clinically useful than simply publishing a long list of CYP enzymes without explaining which interactions have actually been demonstrated.
Laboratory monitoring
Liver Tests and Medication Blood Levels Are Different
Liver-function monitoring
Tests such as ALT, AST, and bilirubin help identify liver-enzyme abnormalities or possible hepatic injury. This is the type of monitoring explicitly required with prescription EPIDIOLEX.
Therapeutic drug monitoring
This measures the concentration of a medication or active metabolite in the bloodstream. It can be useful for selected drugs when interactions, toxicity, loss of control, adherence, pregnancy, organ-function changes, or dose changes make levels clinically informative.
Not every medication requires routine serum drug levels, and not every person using CBD needs routine liver testing. The monitoring plan should be medication-specific and patient-specific.
Antiseizure-drug example: Gaston et al. monitored serum antiseizure-drug levels and liver tests during CBD treatment.
Prescription CBD vs. Full-Spectrum
Does Prescription-CBD Interaction Evidence Apply Directly to Full-Spectrum CBD?
It informs the safety discussion, but it should not be treated as an exact risk estimate for every Full-Spectrum product. Prescription cannabidiol is a standardized purified drug. Full-Spectrum hemp extracts contain CBD within a broader botanical matrix that can include minor cannabinoids, cannabinoid acids, terpenes, and trace THC.
Those constituents may alter pharmacology, absorption, metabolism, or tolerability. That possibility is one reason formulation deserves study. However, controlled human drug-interaction data on well-characterized Full-Spectrum products remain much more limited than the prescription-CBD literature.
What we can responsibly say: purified-CBD studies demonstrate that cannabidiol itself can alter some drugs and laboratory values. They do not prove that every Full-Spectrum product at every dose creates the same interaction magnitude, and Full-Spectrum composition does not prove protection from drug interactions.
For a detailed discussion of purified CBD, Full-Spectrum formulation, dose, liver safety, and the Entourage Effect, see Epidiolex vs. Full-Spectrum CBD. For formulation and absorption, see CBD Absorption and Bioavailability and Full-Spectrum CBD vs. CBD Isolate.
Bring useful information
What to Ask Your Pharmacist or Prescriber Before Using CBD
Bring a batch-specific Certificate of Analysis when possible. A COA can help confirm cannabinoid content, but it cannot determine whether CBD is medically appropriate for a person's medication regimen.
Who deserves extra caution?
Situations Where Professional Review Matters More
Polypharmacy
Taking several medications increases the number of possible pharmacokinetic and pharmacodynamic interactions.
Liver disease or abnormal labs
Existing liver impairment can alter drug and CBD exposure and may change monitoring needs.
Narrow-therapeutic-index drugs
Small concentration changes can matter more for medications that require tight control.
Pregnancy or breastfeeding
CBD should not be treated as routine self-care in pregnancy or lactation.
Children or medically fragile adults
These groups warrant individualized clinical oversight rather than general consumer guidance.
Seizure disorders
Antiseizure medications, therapeutic drug levels, sedation, and liver monitoring may all be relevant.
Common questions
CBD Drug Interaction FAQ
Can CBD interact with medication?
Yes. CBD can alter the concentration or effects of some medications, but the strength of evidence varies by drug. A pharmacist or prescriber should evaluate the exact medication, CBD exposure, product, and patient context rather than relying on a generic interaction list.
What is the difference between a pharmacokinetic and pharmacodynamic interaction?
A pharmacokinetic interaction changes how much drug is present in the body, while a pharmacodynamic interaction changes the combined effect of substances even when drug concentrations may not change substantially.
Does CBD affect the liver?
CBD is metabolized through liver pathways, but metabolism is not the same as liver injury. Purified CBD at sufficient exposure has produced ALT and AST elevations in human trials. Certain medication combinations, particularly valproate with prescription cannabidiol, can increase that risk.
Can CBD interact with clobazam or valproate?
Yes, but in different ways. CBD can substantially increase exposure to N-desmethylclobazam, clobazam's active metabolite. With valproate, the major clinical concern is increased liver-enzyme elevation risk rather than a large increase in valproate concentration.
Can CBD interact with warfarin?
Published case reports describe increased INR with cannabinoid exposure in some people taking warfarin. The evidence is low quality and does not establish the same interaction for every anticoagulant, but warfarin users should discuss CBD with the clinician managing anticoagulation.
Can CBD interact with antidepressants?
It can interact with some antidepressants, but the effect is medication-specific. Human studies have found increased citalopram and amitriptyline exposure with CBD under the studied conditions. Those findings should not automatically be generalized to every antidepressant.
If my medication has a grapefruit warning, does that automatically mean I cannot use CBD?
No. Grapefruit and CBD are not the same substance, and a grapefruit warning is not a validated shortcut for predicting a clinically important CBD interaction. Ask a pharmacist to evaluate the actual medication and evidence.
Should medication blood levels or liver tests be checked when using CBD?
Sometimes. Liver-function tests and therapeutic drug monitoring answer different questions. The need for either depends on the medication, CBD exposure, liver health, symptoms, and clinical context.
Does prescription-CBD interaction evidence apply directly to Full-Spectrum CBD?
It is relevant because Full-Spectrum products contain CBD, but it is not an exact risk estimate for every Full-Spectrum product. Dose, formulation, other cannabinoids, food, route, metabolism, and the specific medication can all change exposure and clinical significance.
Primary and clinical references
Sources Used for This Guide
- DailyMed: current EPIDIOLEX prescribing information, revised May 2026
- Nader et al. (2025): Evidence of Potential Drug Interactions Between Cannabidiol and Other Drugs
- Florian et al. (2025): Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults
- Morrison et al. (2019): CBD interactions with clobazam, stiripentol, and valproate
- Gaston et al. (2017): Cannabidiol and commonly used antiepileptic drugs
- Smythe et al. (2023): Anticoagulant drug interactions with cannabinoids
- Salcedo et al. (2026): CBD interaction study with citalopram and morphine
- Low-dose cannabidiol interaction study with amitriptyline and tramadol
Last evidence review: November 3, 2026. Medication labeling and interaction evidence can change. The treating pharmacist or prescriber should use current drug information for individual decisions.
